Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 8/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | BPTF | Q12830 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411128 | 1.00 | HTR2C (0.61) | HTR2CHTR2APRKCIHTR1DNOS3 | |
| SCHEMBL6928247 | 0.91 | PRKCI (0.51) | HTR2CHTR2APRKCIHTR1DNOS3 | |
| SCHEMBL1122347 | 0.87 | HTR2C (0.64) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL30408910 | 0.84 | SCN9A (0.55) | HTR2CHTR2APRKCINOS3NOS1 | |
| SCHEMBL4007913 | 0.84 | SCN9A (0.55) | HTR2CHTR2APRKCINOS3NOS1 | |
| SCHEMBL4413691 | 0.83 | PRKCI (0.50) | HTR2CHTR2APRKCIHTR6EGFR | |
| SCHEMBL16939364 | 0.82 | HTR2C (0.63) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL23902711 | 0.82 | PRKCI (0.45) | HTR2CHTR2APRKCIHTR1DNOS3 | |
| SCHEMBL30364649 | 0.82 | PRKCI (0.45) | HTR2CHTR2APRKCIHTR1DNOS3 | |
| SCHEMBL3650822 | 0.81 | PRKCI (0.59) | HTR2CHTR2APRKCIHTR6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116143773-B | 2-amino-4-thiazolylpyrimidine compound and preparation method and application thereof | 中国药科大学 | 2023-07-21 | — | — | CN | disclosed |
| CN-116143773-A | 2-amino-4-thiazolylpyrimidine compound and preparation method and application thereof | 中国药科大学 | 2023-05-23 | — | — | CN | disclosed |
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-11007197-B2 | EGFR modulators and uses thereof | ACEA Therapeutics, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200377520-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-20200129516-A1 | NOVEL EGFR MODULATORS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2020-04-30 | — | — | US | disclosed |
| US-10596174-B2 | Pyrrolopyrimidine compounds as inhibitors of protein kinases | ACEA Therapeutics, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-3604306-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2020-02-05 | — | — | EP | disclosed |
| US-10449196-B2 | EGFR modulators and uses thereof | ACEA Therapeutics, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2019037678-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海迪诺医药科技有限公司 | 2019-02-28 | — | — | WO | disclosed |
| WO-2005013977-A1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| EP-1418906-A1 | AMINOALKYL-SUBSTITUTED AROMATIC BICYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-05-19 | — | — | EP | disclosed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
| WO-2003015769-A1 | AMINOALKYL-SUBSTITUTED AROMATIC BICYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10596174-B2 | Pyrrolopyrimidine compounds as inhibitors of protein kinases | BMX, BLK, ITK | HTR2C 3035/4885HTR2A 3728/4885PRKCI 1022/4885 |
| US-10449196-B2 | EGFR modulators and uses thereof | EGFR, ERBB2, ERBB3 | HTR2C 1920/4885HTR2A 1556/4885PRKCI 142/4885 |
| US-20200377520-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | WEE1, WEE2, PDPK1 | HTR2C 2998/4885HTR2A 4484/4885PRKCI 705/4885 |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR2C 19/4885HTR2A 45/4885PRKCI 1977/4885 |
| US-11007197-B2 | EGFR modulators and uses thereof | EGFR, ERBB2, ERBB3 | HTR2C 1920/4885HTR2A 1556/4885PRKCI 142/4885 |
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | WEE1, WEE2, PDPK1 | HTR2C 2998/4885HTR2A 4484/4885PRKCI 705/4885 |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR2C 19/4885HTR2A 45/4885PRKCI 1977/4885 |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR2C 19/4885HTR2A 45/4885PRKCI 1977/4885 |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR2C 19/4885HTR2A 45/4885PRKCI 1977/4885 |
| US-20200129516-A1 | NOVEL EGFR MODULATORS AND USES THEREOF | EGFR, ERBB2, ERBB3 | HTR2C 2209/4885HTR2A 1905/4885PRKCI 159/4885 |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR2C 19/4885HTR2A 45/4885PRKCI 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.